Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MTCR Metacrine (MTCR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Metacrine Stock (NASDAQ:MTCR) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Metacrine alerts:Sign Up Key Stats Today's Range$0.58▼$0.5950-Day Range$0.55▼$0.5952-Week Range$0.30▼$0.59Volume83,889 shsAverage Volume225,834 shsMarket Capitalization$24.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive MTCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter. Email Address MTCR Stock News HeadlinesU.S. sending powerful defense system to Israel, deepening its involvement in the conflictNovember 11, 2024 | nbcnews.comNorth Korea: 6 Experts on How We Can Solve the ProblemOctober 25, 2024 | time.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 15, 2024 | Crypto Swap Profits (Ad)'Iran made a big mistake': Israel promises revenge after missile attackOctober 4, 2024 | usatoday.comUkraine summons Iranian diplomat as Tehran denies missile transfer to RussiaSeptember 12, 2024 | reuters.comRussia strikes Ukraine's power grid in 'most massive' attack of warAugust 28, 2024 | reuters.comCuban regime’s reported return to meddling in US elections a ‘badge of honor’ for targeted criticsAugust 1, 2024 | foxnews.comUS says China is boosting Russia's war machine in UkraineApril 17, 2024 | reuters.comSee More Headlines MTCR Stock Analysis - Frequently Asked Questions How were Metacrine's earnings last quarter? Metacrine, Inc. (NASDAQ:MTCR) announced its earnings results on Thursday, May, 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.06. When did Metacrine IPO? Metacrine (MTCR) raised $84 million in an IPO on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager. What other stocks do shareholders of Metacrine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Outlook Therapeutics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR). Company Calendar Last Earnings5/13/2021Today11/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MTCR CUSIPN/A CIK1634379 Webwww.metacrine.com Phone858-369-7800FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-59.33% Debt Debt-to-Equity Ratio0.34 Current Ratio12.15 Quick Ratio12.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.43Miscellaneous Outstanding Shares42,570,000Free Float36,695,000Market Cap$24.75 million OptionableNot Optionable Beta-0.73 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MTCR) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metacrine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metacrine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
